Clinical research jobs provider Emergent BioSolutions has today (August 26th) announced that the results of its phase I clinical trial into anthrax are to be published.
The biopharmaceutical company reported that its new investigational vaccine Anthrax Vaccine Absorbed research would be featured in an upcoming issue of Vaccine.
As part of the study, which included 69 subjects, scientists noted an accelerated and enhanced immune response to the treatment in healthy participants.
Daniel J Abdun-Nabi, president and operating officer of Emergent BioSolutions, stated that the organisation was pleased to share the results in the upcoming medical journal.
"[The treatment's] characteristics could increase the attractiveness of this product candidate to potentially support the US government's multi-product strategy in stockpiling medical countermeasures," he added.
Earlier this month, members of the biopharmaceutical company's senior management team webcasted a presentation regarding its activities and financial performance at the Wedbush 2011 Life Sciences Conference in New York.